Redx Pharma Plc – Product Pipeline Review

Global Markets Direct’s, ‘Redx Pharma Plc – Product Pipeline Review – 2016’, provides an overview of the Redx Pharma Plc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Redx Pharma Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Redx Pharma Plc

The report provides overview of Redx Pharma Plc including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Redx Pharma Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Redx Pharma Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Redx Pharma Plc’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Redx Pharma Plc

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Redx Pharma Plc’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Redx Pharma Plc Snapshot 5

Redx Pharma Plc Overview 5

Key Information 5

Key Facts 5

Redx Pharma Plc - Research and Development Overview 6

Key Therapeutic Areas 6

Redx Pharma Plc - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Redx Pharma Plc - Pipeline Products Glance 13

Redx Pharma Plc - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 14

Redx Pharma Plc - Drug Profiles 15

RDX-001 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

RDX-002 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

RDX-003 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

RDX-004 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Small Molecules to Inhibit DNA Gyrase for Neisseria Gonorrhoeae Infections 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Small Molecules for Bacterial Infections 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Small Molecules for Hepatitis B 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Small Molecules for Oncology 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Small Molecules to Inhibit IDO for Solid Tumors 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Small Molecules to Inhibit Neuraminidase for Influenza A and B Infections 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Small Molecules to Inhibit Pan-Raf Kinases for Colorectal Cancer 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Redx Pharma Plc - Pipeline Analysis 27

Redx Pharma Plc - Pipeline Products by Target 27

Redx Pharma Plc - Pipeline Products by Route of Administration 28

Redx Pharma Plc - Pipeline Products by Molecule Type 29

Redx Pharma Plc - Pipeline Products by Mechanism of Action 30

Redx Pharma Plc - Recent Pipeline Updates 31

Redx Pharma Plc - Dormant Projects 32

Redx Pharma Plc - Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Appendix 34

Methodology 34

Coverage 34

Secondary Research 34

Primary Research 34

Expert Panel Validation 34

Contact Us 34

Disclaimer 35

List of Tables

List of Tables

Redx Pharma Plc, Key Information 5

Redx Pharma Plc, Key Facts 5

Redx Pharma Plc – Pipeline by Indication, 2016 7

Redx Pharma Plc – Pipeline by Stage of Development, 2016 9

Redx Pharma Plc – Monotherapy Products in Pipeline, 2016 10

Redx Pharma Plc – Partnered Products in Pipeline, 2016 11

Redx Pharma Plc – Partnered Products/ Combination Treatment Modalities, 2016 12

Redx Pharma Plc – Preclinical, 2016 13

Redx Pharma Plc – Discovery, 2016 14

Redx Pharma Plc – Pipeline by Target, 2016 27

Redx Pharma Plc – Pipeline by Route of Administration, 2016 28

Redx Pharma Plc – Pipeline by Molecule Type, 2016 29

Redx Pharma Plc – Pipeline Products by Mechanism of Action, 2016 30

Redx Pharma Plc – Recent Pipeline Updates, 2016 31

Redx Pharma Plc – Dormant Developmental Projects,2016 32

Redx Pharma Plc, Other Locations 33

Redx Pharma Plc, Subsidiaries 33

List of Figures

List of Figures

Redx Pharma Plc – Pipeline by Top 10 Indication, 2016 7

Redx Pharma Plc – Pipeline by Stage of Development, 2016 9

Redx Pharma Plc – Monotherapy Products in Pipeline, 2016 10

Redx Pharma Plc – Partnered Products in Pipeline, 2016 11

Redx Pharma Plc – Pipeline by Top 10 Target, 2016 27

Redx Pharma Plc – Pipeline by Route of Administration, 2016 28

Redx Pharma Plc – Pipeline by Molecule Type, 2016 29

Redx Pharma Plc – Pipeline Products by Top 10 Mechanism of Action, 2016 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports